

MICROMEDEX®

NO GAPS, NO INCONSISTENCIES



提供完整的臨床實證 敏捷的檢索，快速提供各種解答

從Micromedex2.0就可輕鬆獲取到藥物、疾病、毒物、檢測與另類輔助醫學等的完整資訊。現在您可以透過更聰明的檢索技術，更快找到解答，大幅節省臨床醫生的寶貴時間，主動支持病患安全。全球超過83個國家的3500家以上的醫院，超過30多年來持續地信賴Micromedex中的實證與同儕評論之臨床決策參考資源。

簡單的檢索

可依照內容需求類別如藥物、疾病、毒物或是全部進行檢索
每個頁面均保留該檢索詞的檢索欄位，便利程度如同您所熟悉的檢索引擎一般
可協助檢索的智慧型文本輸入法，可即時拼字預測使用者需要的關鍵字
相關術語詞建議：可搭配劑量、不良反應等術語詞，直接導入最常用閱讀查詢的內容

節省臨床醫護人員的時間

提供更多諮詢如最新醫藥新聞、訓練課程、常用文件如黑框警告、藥物諮詢報告等以及手機 APP下載協助降低藥物治療的失誤
支持病患安全方案
確保醫院一貫的照護
藉由實證與建議的評讀等級以促進最好的實務醫療

快速的結果

列出查詢藥物所屬分類別
依相關度來排序結果
選擇摘要層級或深入的結果
在整合檢索的頁面中，分別有簡要、深入解答提供藥物、疾病與毒物資訊等的連結。

TRUVEN HEALTH ANALYTICS
MICROMEDEX® SOLUTIONS

我的訂閱 | 關連 | 說明 | 下載中心 | 登出

主頁 | 藥物相互作用 | IV 相容性 | 藥物鑑定 | 藥物比較 | CareNotes® | NeoFax® / Pediatrics | 其他工具 ▼

全部 | 藥物 | 疾病 | 毒理學

搜尋藥物、疾病、毒理學及其他資訊

搜尋 Micromedex

最新消息

- A Special Thank You from Micromedex...
- Redefine Your Micromedex Experience...
- The Countdown to ASHP Midyear...
- Attending IHL 2014? Discover How to...
- Fatal Case of PML Reported with...

Read Top News ▶

支援和訓練

- Citing Micromedex
- Clinical Consulting & Services
- Integrated Content Options for MU & More
- Tips & Tricks
- Training & Tutorials
- User Guide

Support Request ▶

資源


- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS

Download Mobile Apps

© 2014 Truven Health Analytics Inc. | 關於 | 聯絡資訊 | 使用者指南 | 保修與免責聲明 | Micromedex.com


整合性的檢索結果

整合檢索結果頁面上方提供「簡要解答」與「深入解答」或「全部結果」查詢。當使用者輸入關鍵詞後，將進入「簡要解答」查閱，若想查看所有相關資訊，可切換到「全部結果」分頁觀看。左方綱要方式提供藥物交互作用、靜脈注射相容性、藥物比較療效、疾病與毒物資訊等。頁面右方「相關結果」亦可連結到Micromedex其他子庫資訊。




智能搜尋功能

當使用者在「深入解答」分頁時觀看詳細文件時，可點選「檢視完整文件」後輸入其他關鍵詞，更快獲得重要訊息。右上方搜尋視窗也提供與主頁面一樣的建議選單功能，讓使用者能更快切入所需資訊。



建議、實證與療效評等

區分等級與詳細評論的研究建議是要讓臨床醫師能有信心地進行決策。



藥物交互作用

在單一頁面中即可連結到多元的藥物交互作用資訊。彩色標籤的資訊可以讓您辨識出，藥物與食物、酒精、懷孕、菸草、懷孕暨哺乳期間與過敏間的不良反應等級。

TRUVEN HEALTH ANALYTICS
MICROMEDEX® SOLUTIONS

查詢 Micromedex

主頁藥物相互作用藥物安全藥物比較CareNotes®NeoFax® / Pediatrics其他工具

Drug Interaction Results

顯示方式：Drug Methyphenidate嚴重性：All文件：All類型：All

詞彙：Drug Drug (13) | 過敏症狀 (0) | 藥物 (0) | 乙醚 (1) | 實驗室 (0) | 抽吸 (0) | 懷孕 (1) | 哺乳 (1)

Drug-Drug 相互作用 (13)

藥物：	嚴重性：	文件：	描述：
METHYLPHENIDATE – MONOAMINE OXIDASE INHIBITORS Methyphenidate interacts with: • 羥基作用藥物	Contraindicated	Fair	Concurrent use of METHYLPHENIDATE and MONOAMINE OXIDASE INHIBITORS may result in hypertensive crisis (headache, palpitation, and neck stiffness).
METHYLPHENIDATE [Systemic] – BUPROPION [Systemic]	Major	Fair	Concurrent use of BUPROPION and METHYLPHENIDATE may result in increased risk of seizure.
DONEPEZIL – SEIZURE LOWERING AGENTS	Major	Fair	Concurrent use of DONEPEZIL and SEIZURE LOWERING AGENTS may result in reduced seizure threshold.

Drug-乙醇 相互作用 (1)

藥物：	嚴重性：	文件：	描述：
ETHANOL [Systemic] – METHYLPHENIDATE [Systemic]	Major	Fair	Concurrent use of METHYLPHENIDATE and ETHANOL may result in additive CNS effects.

Drug-懷孕 相互作用 (1)

藥物：	嚴重性：	文件：	描述：
PREGNANCY – METHYLPHENIDATE [Systemic]	Moderate	Unknown	Methyphenidate is rated as US FDA Category C. Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. (OR) No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Drug-哺乳 相互作用 (1)

藥物：	嚴重性：	文件：	描述：
LACTATION – METHYLPHENIDATE [Systemic]	Major	Unknown	Infant risk cannot be ruled out. Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when Methyphenidate is used during breast-feeding. Weigh the potential benefits of treatment against potential risks before prescribing Methyphenidate during breast-feeding.

定義

嚴重性：
禁忌
嚴重
中等
輕微
未知

文件：
確切
良好
一般
未知

© 2015 Truven Health Analytics Inc. | 關於 | 網站資訊 | 使用與指南 | 服務與免責聲明 | Micromedex.com

比較藥物摘要

透過易於閱讀的表格來選擇多種藥物進行比較。同時可比較與檢視兩種藥物，若有兩種以上藥物，可利用下拉式選單進行與其他藥物比較。另外，也可依治療分類進一步檢索相關文獻資料。

Drug Comparison Results

在欄中顯示 1
PROzac

在欄中顯示 2
Zoloft

更新

詞彙：首頁 | Dosing & Indications | Black Box Warnings | Contraindications/Warnings | Drug Interactions (single) | Adverse Effects | Name Info | Mechanism of Action/Pharmacokinetics | Administration/Monitoring | How Supplied | Toxicology | Clinical Teaching | References

Fluoxetine Hydrochloride
[PROzac]

抽籤 DRUGDEX 中的詳細資訊

Dosing & Indications

Adult Dosing

抽籤 DRUGDEX 中的詳細資訊

- dose change: clinical effect may not be evident for several weeks due to the long elimination half-life of fluoxetine and its major active metabolite, affecting dose titration and withdrawal from therapy [8][9][10]
- discontinuing treatment: gradually reduce dose to avoid withdrawal symptoms; if intolerable symptoms develop, consider resuming therapy at the previously prescribed dose and taper at a slower rate [8][9][10]
- MAOI use: discontinue MAOIs intended to treat psychiatric disorders at least 14 days prior to initiation of fluoxetine, at least 5 weeks should elapse after fluoxetine discontinuation before an MAOI is initiated; if urgent treatment with linezolid or IV methylene blue is required, immediately stop fluoxetine and closely monitor the patient for 5 weeks or until 24 hours after the last dose, whichever comes first, fluoxetine may be resumed 24 hours after the last dose of linezolid or IV methylene blue [8][9][10]
- Bulimia nervosa: 60 mg ORALLY once daily in the morning; may initiate at a lower dose and titrate up; doses greater than 60 mg/day have not been evaluated [8][10][11]
- Depressed bipolar I disorder. In combination with olanzapine: (Pukile(R)) initial, 20 mg ORALLY once daily in the evening in combination with olanzapine 5 mg [8]
- Depressed bipolar I disorder. In combination with olanzapine: (Pukile(R)) titrate to clinical effect and tolerability within the dose range, fluoxetine 20 to 50 mg/olanzapine 5 to 12.5 mg ORALLY once daily each evening; safety of doses greater

Sertraline Hydrochloride
[Zoloft]

抽籤 DRUGDEX 中的詳細資訊

Dosing & Indications

Adult Dosing

抽籤 DRUGDEX 中的詳細資訊

- Major depressive disorder: 50 mg/day ORALLY as a single dose in the morning or the evening; may be increased at intervals of at least 1 week to a MAX dose of 200 mg/day [3]
- Obsessive-compulsive disorder: 50 mg/day ORALLY as a single dose in the morning or the evening; may be increased at intervals of at least 1 week to a MAX dose of 200 mg/day [3]
- Panic disorder: 25 mg/day ORALLY as a single dose in the morning or the evening for 1 week, then increase to 50 mg/day; may then be increased at intervals of at least 1 week to a MAX dose of 200 mg/day [3]
- Posttraumatic stress disorder: 25 mg/day ORALLY as a single dose in the morning or the evening for 1 week, then increase to 50 mg/day; may then be increased at intervals of at least 1 week to a MAX dose of 200 mg/day [3]
- Premenstrual dysphoric disorder: daily dosing, 50 mg/day ORALLY as a single dose in the morning or the evening throughout the menstrual cycle; may be increased at 50-mg increments/menstrual cycle up to 150 mg/day [3], OR
- Premenstrual dysphoric disorder: luteal phase dosing, 50 mg/day ORALLY only during the luteal phase, may be increased up to 100 mg/day if needed; if 100-mg dose is necessary, each new luteal-phase dosing cycle should begin with 50 mg/day for 3 days before increasing to 100-mg/day dose [3]
- Social phobia: 25 mg/day ORALLY as a single dose in the morning or the evening for 1 week, then increase to 50 mg/day; may then be increased at intervals of at least 1 week to a MAX dose of 200 mg/day [3]

靜脈注射相容檢索

藉由可快速辨識的彩色標籤來檢視結果資料。點選結果頁面上方的適當標籤，則可查閱其他靜脈注射傳輸途徑的相容資料。

IV 相容性結果

修改相容性

Selected Drug: Amphotericin B conventional colloidal

SolutionY-SiteAdmixtureSyringeTPN/TNA

相容性: All

Common Solutions Test Detail	Rating	Solution Information
D5W (D5W-Dextrose 5%)	相容	More Solution Information
D10W (Dextrose 10%)	相容	More Solution Information
D5LR (Dextrose 5% in lactated Ringers)	不相容	More Solution Information
D5NS (Dextrose 5% in sodium chloride 0.9%)	不相容	More Solution Information
D5W - 1/2 NS (Dextrose 5% in sodium chloride 0.45%)	未測試	
NS (Normal saline- Sodium chloride 0.9%)	不相容	More Solution Information
1/2 NS (Sodium chloride 0.45%)	未測試	

Other Solutions Test Detail	Rating	Solution Information
Dextrose 15%	相容	More Solution Information
Dextrose 20%	相容	More Solution Information
Fat emulsion (intravenous)	不相容	More Solution Information
Lactated Ringer's Injection	不相容	More Solution Information
Peritoneal dialysis solution	不確定	

Selected Drug: Amphotericin B conventional colloidal

商品名稱: Fungizone intravenous, Amphocin

其他名稱: 未列出內容。

pH range: About pH 5.7 at 0.1 mg/mL in dextrose 5%

毒物

可參考得到關於藥廠、生技、藥品與成份的豐富資訊，同樣也可查找到關於毒性等級、生殖風險與處置原則。

Tox 和藥物產品結果

←

修改搜尋

顯示 找到以下項的結果 "Paracet"

結果來源: 美國 | 其他國家/地區

顯示: 產品名稱名稱 (35) | 代名詞 (0) | 製造商/製造商資訊 (0)

結果以以下欄位顯示 | 結果包含

Results 1 - 35

Page 1 of 1 Go | 前面 | 後面

名稱	強度/ 劑型	製造商	國家/地區	產品 ID	AAPCC 代碼	相關文件
1. Paracetamol (FM)	(Form Not Given)	Adcock Ingram, S.Afr.	South Africa	8150268		ACETAMINOPHEN - DRUGDEX® ASCORBIC ACID - DRUGDEX® CODEINE - DRUGDEX®
2. Paracetamol (FM)	(Form Not Given)	Ratiopharm, Ger.	Germany	8124439		ACETAMINOPHEN/CODEINE PHOSPHATE - DRUGDEX®
3. Paracetamol (FM)	(Form Not Given)	Bright Future, Hong Kong	Hong Kong	7975543		ACETAMINOPHEN - DRUGDEX®
4. Paracetamol and Caffeine Tablets BP 2014	(Form Not Given)			8025568		ACETAMINOPHEN - DRUGDEX® CAFFEINE - DRUGDEX®
5. Paracetamol Capsules BP 2014	(Form Not Given)			8024492		ACETAMINOPHEN - DRUGDEX®
6. Paracetamol C & F (FM)	(Form Not Given)	Pharmiana, Hong Kong	Hong Kong	8164625		ACETAMINOPHEN - DRUGDEX® CHLORPHENIRAMINE - DRUGDEX® PSEUDOEPHEDRINE - DRUGDEX®
7. Paracetamol C & F (FM)	(Form Not Given)	Pharmiana, Malaysia	Malaysia	8047388		ACETAMINOPHEN - DRUGDEX® CHLORPHENIRAMINE - DRUGDEX® PSEUDOEPHEDRINE - DRUGDEX®
8. Paracetamol, Codeine Phosphate and Caffeine Capsules BP 2014	(Form Not Given)			8140215		ACETAMINOPHEN - DRUGDEX® CAFFEINE - DRUGDEX® CODEINE - DRUGDEX®
9. Paracetamol, Codeine Phosphate and Caffeine Tablets BP 2014	(Form Not Given)			8140566		ACETAMINOPHEN - DRUGDEX® CAFFEINE - DRUGDEX® CODEINE - DRUGDEX®
10. Paracetamol comp (DI)	(Form Not Given)	Apotex, Neth.	Netherlands	8105876		ACETAMINOPHEN - DRUGDEX® CAFFEINE - DRUGDEX®
11. Paracetamol comp (FM)	(Form Not Given)	Alud, Ger.	Germany	8122479		ACETAMINOPHEN/CODEINE PHOSPHATE - DRUGDEX®
12. Paracetamol Oral Suspension BP 2014	(Form Not Given)			8114371		ACETAMINOPHEN - DRUGDEX®
13. Paracetamol plus (FM)	(Form Not Given)	CT, Ger.	Germany	8112093		ACETAMINOPHEN - DRUGDEX® CAFFEINE - DRUGDEX®
14. Paracetamol Plus (FM)	(Form Not Given)	Pharmiana, Malaysia	Malaysia	8103801		DEXTROMETHORPHAN - DRUGDEX® ACETAMINOPHEN - DRUGDEX® PSEUDOEPHEDRINE - DRUGDEX®

